Please activate JavaScript!
Please install Adobe Flash Player, click here for download
ePaper created 2017-03-15, 10:03:19 | version 1.38.0
06 BUSINESS Dental Tribune Asia Pacific Edition | 3/2017 Koelnmesse Singapore: Mathias Kuepper assumes management position By DTI SINGAPORE: Having shared the management position with Mi- chael Dreyer for an interim pe- riod since June 2016, Mathias Kuepper will now assume sole responsibility as Managing Di- rector of Koelnmesse Pte Ltd in Singapore. The Asian subsidiary of German event organiser Koeln- messe was established under Dreyer in 2002 and organises leading dental events IDEM Sin- gapore and the Association of Or- thodontists (Singapore) Confer- ence, among others. Paying tribute to Dreyer’s contribution to the company, Koelnmesse CEO Gerald Böse ac- knowledged that Dreyer helped launch and sustain a substantial part of Koelnmesse’s internation- alisation efforts right from the start and ultimately ensured the success of these efforts. Further- more, Böse said he was pleased to welcome long-standing staff member Kuepper as the new managing director of the Asia branch. Kuepper, who is an economic geographer with extensive event and project management experi- ence, has been working for Koeln- messe Singapore since 2002. Hav- ing been involved in the strategic business development in the Asian economic region for many years, he is set to focus on the implementation of Koelnmesse events in South East Asia and on the expansion of business activi- ties in the local market. With the change in staff, Koeln- messe’s centralised manage- ment performed by one regional Mathias Kuepper centre for all of Asia will now be re- placed with a market-specific de- centralised organisational struc- ture that works in close collabora- tion with the parent company in Cologne, the event organiser announced. Deal collapses: Straumann decides against investing in MegaGen By DTI DAEGU, Souih Korea/BASEL, Swiizer- land: Global dental implant manu- facturer Straumann has announ- ced that it will no longer be pursu- ing its plans to invest in or partner with the South Korean implant company MegaGen Implant. In- stead of converting its US$30 mil- lion bond into MegaGen shares, the group has received full repay- ment in cash with interest. In 2014, Straumann pur- chased convertible bonds from MegaGen and announced that it would be exercising its right to convert these bonds into shares to acquire a controlling stake in MegaGen in July last year. After the announcement, MegaGen disputed the conver- sion price and calculation proce- dure, and despite significantly increased offers from Strau- mann, initiated arbitration under the International Chamber of Commerce rules. This could have taken up to two years, depending on the progress of the arbitra- tion. corresponding long delay are not in the interest of either company and together with other recent developments make the busi- ness case unattractive,” ex- plained Straumann CEO Marco Gadola. “The collaborative spirit of partnership that characterised our relationship disappeared when MegaGen’s owners initi- ated arbitration. This and the “Due to the urgent need to expand in the fast-growing non- premium segment in China, India, Russia and Eastern Europe, we have invested in strong part- ners like Anthogyr, Equinox Me- dentika and Zinedent—in addi- tion to Neodent. The Straumann Group brand, our shared tech- nology platform and global net- work offer them considerable leverage and we are very excited about the opportunities that our partnership with them is creat- ing. Strategically, there is no longer a compelling need for a collaboration with MegaGen,” he added. AD IDS 2017 Booth: V15 Hall: 10.2 Light-curing micro-hybrid composite (cid:149) applicable for various indications and all cavity classes (cid:149) high translucency and a perfect colour adaption (cid:149) Polishable to a high gloss (cid:149) excellent physical properties for durable fillings (cid:149) high filler content (cid:149) packable consistency (also available as Composan LCM flow) Glass Ionomer Filling Cement (cid:149) For fillings of classe I, III and IV (cid:149) Excellent biocompatibility and low acidity (cid:149) High compressive strength (cid:149) No temperature rise during setting (cid:149) Enamel-like translucency (cid:149) Excellent radiopacity (cid:149) Stable and abrasion resistant Visit www.promedica.de to see all our products Dental Material GmbH 24537 Neumünster / Germany +49 43 21 / 5 41 73 Tel. +49 43 21 / 5 19 08 Fax eMail info@promedica.de Internet www.promedica.de © Koelnmesse© Koelnmesse